Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 to an estimated $381.5 billion by 2033. ... The Case for Eli Lilly Stock.

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. ... The growth in its new GLP-1 drugs has transformed the business in a strong, ...

I'm a growth and value investor, and Eli Lilly slots perfectly into the nexus of my strategy. With 12-month upside of 30-50% in a base-bull case, not buying Eli Lilly stock now is foolish.

Eli Lilly (NYSE: LLY) stock hasn't been doing too well this year, but that could change later this month. A couple of key events are on the horizon this month during which the company will release ...